The study by Lengfelder et al 1 (August issue) reporting the results of the German AML Cooperative Group on front-line therapy for acute promyelocytic leukemia (APL) contains several statements that deserve critical comment. To begin with, their conclusion that 'the intensity of the induction chemotherapy combined with ATRA is one of the factors which has critical influence on the outcome of APL' is neither supported by their own results, nor by data reported in the other large cooperative APL trials. In fact, comparable or even better results in terms of hematological and molecular remission, and overall event-free and relapse-free survival rates have been extensively and consistently reported in other recent studies in which much less intensive induction and consolidation chemotherapy were given.
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The study by Lengfelder et al 1 (August issue) reporting the results of the German AML Cooperative Group on front-line therapy for acute promyelocytic leukemia (APL) contains several statements that deserve critical comment. To begin with, their conclusion that 'the intensity of the induction chemotherapy combined with ATRA is one of the factors which has critical influence on the outcome of APL' is neither supported by their own results, nor by data reported in the other large cooperative APL trials. In fact, comparable or even better results in terms of hematological and molecular remission, and overall event-free and relapse-free survival rates have been extensively and consistently reported in other recent studies in which much less intensive induction and consolidation chemotherapy were given. [2] [3] [4] [5] As expected, therapeutic efficacy was accompanied in these series of studies by less toxicity and better compliance to the protocol. Because these results were obtained with standard doses or even without cytarabine, we believe that there is no justification for Lengfelder et al to suggest the need for a randomized trial to assess the value of an induction therapy including ATRA and high-dose ara-C in comparison with standard-dose ara-C. In fact, the most representative cooperative groups have recently designed new front-line therapy protocols for APL, which explore the possibility of reducing treatment intensity by eliminating cytarabine, or even all kinds of chemotherapy, 6 at least for low risk patients.
A further questionable issue in the study by Lengfelder et al is the presumed comparability of their results with those reported in the Italian, Spanish and European APL-93 studies, which are regarded as 'the most appropriate ones for comparison with our data'. In this respect, patient age (a well-known risk factor for induction response) was significantly different in the German study, in which only adult patients aged less than 60 years were enrolled. By contrast, the GIMEMA, APL-93 and PETHEMA studies also included either pediatric patients or adult patients up to the age of 75 years. In particular, patients in the PETHEMA study aged younger than 15 years and older than 60 years had an induction response rate of 71%. This dropped to 50% in patients older than 70 years (P = 0.007). However, patients with comparable age ranges had response rates of 94% and 92% in the PETHEMA and German series, respectively. Furthermore, the small sample size of the German study leads to wide confidence intervals for complete remission, relapse and survival rates.
We also wish to comment on the molecular remission (MR) rate after induction and consolidation reported by Lengfelder et al (91% and 92%, respectively). We submit that a single induction course with idarubicin alone, as used in the Italian and the Spanish studies, is not comparable with a double chemotherapy induction strategy with TAD/HAM, as used in the German study. However, when MR was evaluated after consolidation, both the Italian and the Spanish studies reported MR rates of 98% and 93%, respectively. The other statistical parameters regarding the outcome of patients who achieved remission also require comment. Lengfelder et al appear to overestimate their results when they write: 'As compared to the other studies with a similar median observation time, a particularly low relapse rate was observed in our patients'. In our opinion, the results in terms of relapse risk, and overall and leukemia-free survival are similar to but not better than those reported by the GIMEMA, PETHEMA and European APL studies. 2, 4, 5 In this regard, the authors of the German study should take into account that their cumulative dose of anthracyclines was comparable with or even higher than that used in the other studies. Thus, it is unclear which contribution, except that of increased toxicity and poorer protocol compliance, is achieved by the inclusion of HD/ara-C in the treatment of newly diagnosed APL. 
